Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06898047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Consistency of Response With Rimegepant in Acute Treatment of Migraine

Study acronym: CORRELATE-UK
StatusActive, Not Recruiting
PhaseNot specified
SponsorPfizer
Started2025-11-15
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 31, 2026 → Oct 31, 2026
See other at-risk trials from Pfizer

Amendment history

2026-09-22
Primary completion pushed: 2026-07-31 → 2026-10-31
Completion pushed: 2026-07-31 → 2026-10-31
2026-05-01
Study Status, Arms and Interventions, Outcome Measures v8
Trial arms changed: 1 → 2
Primary completion pushed: 2026-06-30 → 2026-07-31
Secondary endpointsdetails revised at 3 of 3 entries
2026-01-12
Study Status v7
Re-verified, no change to tracked fields
2025-12-12
Study Status, References v6
Completion date2026-06-30→2026-07-31
2025-11-24
Not Yet Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Active, Not Recruiting
Primary completion date2026-05-29→2026-06-30
Completion date2026-05-29→2026-06-30
Start dateestimated 2025-09-17→confirmed 2025-11-15
Study sites0→1
Show 4 earlier versions
2025-09-02
Study Status v4
Primary completion date2026-03-31→2026-05-29
Completion date2026-03-31→2026-05-29
Start date2025-08-01→2025-09-17
2025-08-05
Study Status v3
Re-verified, no change to tracked fields
2025-07-02
Study Status v2
Primary completion date2026-09-15→2026-03-31
Completion date2026-09-15→2026-03-31
Start date2025-04→2025-08-01
2025-04-08
Study Status v1
Start date2025-03-31→2025-04
2025-03-20
Original filing
Pfizer
431 trials monitored
See 32 trials at risk
Migraine
463 trials monitored
See 25 trials at risk
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.
Trial Details
NCT Number NCT06898047
Lead Sponsor Pfizer
Conditions Migraine
Enrollment 250 participants
Start Date 2025-11-15
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-21